Matt Panuwat has been appointed chief business officer at ORIC Pharmaceuticals, a clinical-stage oncology company focused developing novel therapies against treatment-resistant cancers. Mr. Panuwat will serve on the executive leadership team and will lead business and corporate development. 
 
Mr. Panuwat previously served as senior vice president of business development at Prothena, where he led partnership activities and established the company’s global R&D collaboration with Celgene. Prior to Prothena, he was head of business development at Medivation, where he led M&A and licensing activities, including the acquisition of talazoparib from BioMarin, until Medivation’s acquisition by Pfizer.  
 
“ORIC continues to attract top talent to its leadership team with our newest addition, Matt Panuwat. Over the past two decades, his work in the biotechnology industry has spanned a broad range of scientific, financial and strategic positions,” said Jacob Chacko, MD, chief executive officer of ORIC. “Matt’s prior leadership roles at Prothena and Medivation, along with his experience as a healthcare investment banker, will be critical to ORIC’s future as we expand our internal pipeline of agents targeting oncology resistance and look to establish partnerships related to our existing programs.”